论文部分内容阅读
目的:探讨活动性代偿期乙肝肝硬化患者采用阿德福韦酯片治疗的临床效果及其对患者病变过程的影响。方法:将40例乙肝肝硬化患者随机分为观察组和对照组,每组各20例患者,治疗48周后,对两组患者的变化进行观察,对不良反应情况进行对比。结果:治疗48周后,各项检查指标,观察组明显高于对照组,具有统计学差异(P<0.05);不良反应情况,观察组少于对照组。结论:乙肝肝硬化患者采用阿德福韦酯进行治疗,能够对乙肝病毒进行有效抑制,对肝功能进行改善,对患者的病情发展进行控制。
Objective: To investigate the clinical effect of adefovir dipivoxil tablets in active decompensated patients with hepatitis B cirrhosis and its effect on the pathological changes of patients. Methods: Forty patients with hepatitis B cirrhosis were randomly divided into observation group and control group, with 20 patients in each group. After 48 weeks of treatment, the changes of two groups of patients were observed, and the adverse reactions were compared. Results: After the treatment for 48 weeks, the indexes in the observation group were significantly higher than those in the control group (P <0.05). The adverse reactions were less in the observation group than in the control group. Conclusion: Treatment of patients with hepatitis B cirrhosis with adefovir dipivoxil can effectively suppress hepatitis B virus, improve liver function and control the development of the disease.